Ex­clu­sive: GSK CEO Em­ma Walm­s­ley talks about vac­cines, M&A and the com­pa­ny’s fu­ture

British drug gi­ant GSK is at an in­flec­tion point. The com­pa­ny shed its con­sumer unit Ha­le­on and plans to put the pro­ceeds in­to build­ing out its pipeline. It just had an RSV vac­cine ap­proved, and it’s done a $2 bil­lion deal for Bel­lus Health and its chron­ic cough med­i­cine.

End­points News‘ Drew Arm­strong sat down with Walm­s­ley in Cam­bridge, MA, to talk about the com­pa­ny’s strat­e­gy over the next sev­er­al years, how it’ll sell down and spend its re­main­ing stake in Ha­le­on and the im­por­tance of vac­cines to the com­pa­ny’s fu­ture.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER